ロード中...
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
PURPOSE: Regorafenib, an oral multikinase inhibitor, has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients that have progressed after all standard therapies. However, novel strategies to improve tolerability and enhance anti-cancer efficacy are needed. EXPERIMENTAL DESIGN...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5620258/ https://ncbi.nlm.nih.gov/pubmed/28978118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20054 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|